Revolution Medicines

Revolution Medicines

Organization

Heard in 17 episodes across 12 shows since Oct 2025

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering, developing, and delivering targeted medicines for patients with RAS-addicted cancers. Its pipeline includes RAS pathway inhibitors, including daraxonrasib (RMC-6236).

Discussed inMarkets100%

Episodes

17
across 12 shows

This week

0
episodes on 0 shows

Expert statements

11
9 positive · 2 negative

Share of the conversation

Mentions of Revolution Medicines per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.

0.0‰0.02‰0.04‰0.06‰0.08‰Aug 25Sep 16Oct 9Oct 31Nov 22
Show the data
DayShare (7-day)Mentions
Aug 260.03‰2
Aug 280.03‰1
Sep 10.04‰1
Sep 130.02‰2
Oct 160.01‰1
Oct 200.02‰1
Oct 270.01‰1
Oct 300.03‰2
Nov 60.02‰2
Nov 90.03‰2
Nov 120.04‰1
Nov 130.03‰1
Nov 150.07‰5

The full trend: rank, tone and why it is trending →

Email alert

Email me when Revolution Medicines comes up on a podcast

One email a week at most, with the new episodes that mention Revolution Medicines. Free, no account needed, unsubscribe in one click.

What experts have said about Revolution Medicines

11 statements · 9 positive · 2 negative

  1. Matthew CloutierPositiveNov 15, 2026· Breaking Biotech

    Revolution Medicines’ decline created an opportunity to buy shares.

    “So it's down a little bit, but I saw it as an opportunity to take a long position.”

    Listen at 1:15

    Open the episode · 122 - Breaking Biotech Week End Wrap Up - Nov 14, 2026
  2. Matthew CloutierPositiveNov 15, 2026· Breaking Biotech

    Revolution Medicines remains a pioneer in RAS-mediated cancer treatment.

    “I still see RevMed as being, you know, the pioneer in RAS-mediated cancers.”

    Listen at 22:50

    Open the episode · 122 - Breaking Biotech Week End Wrap Up - Nov 14, 2026
  3. Matthew CloutierPositiveNov 15, 2026· Breaking Biotech

    Revolution Medicines’ valuation does not fully reflect future upside.

    “a $36 billion valuation is sort of pricing out some of the upside that I think is yet to come.”

    Listen at 23:07

    Open the episode · 122 - Breaking Biotech Week End Wrap Up - Nov 14, 2026

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

17 episodes featuring Revolution Medicines, newest first